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Genes and human brain evolution
Several genes were duplicated during human evolution. It seems that one such duplication gave rise to a gene that may have helped to make human brains bigger and more adaptable than those of our ancestors.
DA N I E L H . G E S C H W I N D & G E N E V I E V E KO N O P K A
T he decoding of the human and chimpanzee genomes was heralded as an opportunity to truly understand how changes in DNA resulted in the evolution of our cognitive features. However, more than a decade and much detective work later, the functional consequences of such changes have proved elusive, with a few exceptions 1, 2 . Now, writing in Cell, Dennis et al. 3 and Charrier et al. 4 describe the evolutionary history and function of the human gene SRGAP2 and provide evidence for molecular and cellular mechanisms that may link the gene's evolution with that of our brain*.
It was already known that SRGAP2 is involved in brain development 5 and that humans have at least three similar copies of the gene, whereas non-human primates carry only one 6 . However, the study of duplicated, or very similar, segments of DNA is hampered by the fact that most human cells carry two sets of chromosomes (one inherited from each parent), which makes it difficult to distinguish duplicated copies from the different parental forms of the gene. To circumvent this problem, Dennis et al. 3 searched for copies of SRGAP2 in the genome of a hydatidiform mole -an abnormal, non-viable human embryo that results from the fusion of a sperm with an egg that has lost its genetic material; it therefore has chromosomes derived from a single parent.
The authors showed that humans carry four non-identical copies (named A-D) of SRGAP2 at different locations on chromosome 1. By comparing the genes' sequences with that of the SRGAP2 gene from the orangutan and chimpanzee, the authors estimated that SRGAP2 was duplicated in the human lineage about 3.4 million years ago, resulting in SRGAP2A (the ancestral version that we share with other primates) and SRGAP2B. Further duplications of SRGAP2B gave rise to SRGAP2C about 2.4 million years ago and to SRGAP2D about 1 million years ago (Fig. 1a) .
Dennis et al. found that SRGAP2B and SRGAP2D are expressed at much lower levels, and are more prone to sequence variations among humans, than are the A and C copies. They therefore suggest that SRGAP2C might have played a major part in the emergence of the Homo lineage 2 million to 3 million years ago, when human brain specializations (such as those leading to the development of language, social cognition and problem solving) were probably evolving. 
E D U A R D O V I L A R & J O S E P TA B E R N E R O
S ome tumours carry mutations that confer resistance to specific drugs, precluding the use of these drugs in patients with these mutations. However, drug resistance can arise even when a tumour does not seem to meet these criteria. In this issue, Misale et al. 1 (page 532) and Diaz et al. 2 (page 537) report that a commonly acquired drug resistance in colorectal cancer can be explained by rare tumour cells that have mutations in a particular gene, KRAS, and that outgrow susceptible cancer cells during drug exposure. Excitingly, the two research groups demonstrate that they can detect this mutation in the tumour DNA that circulates freely in a patient's bloodstream. Their findings highlight the potential for blood samples to be used in the diagnosis and monitoring of cancers, thereby reducing the need for more-invasive procedures such as tumour biopsies.
Patients with colorectal cancers are often treated with drugs that target epidermal growth factor receptor (EGFR), a signalling protein that activates cellular proliferation. A key predictor of a person's suitability for anti-EGFR therapy is whether their cancerous cells contain a mutated form of KRAS; the KRAS protein functions downstream of EGFR, such that cells with overactive KRAS will not respond to anti-EGFR therapies. The use of KRAS mutations for predicting the effectiveness of anti-EGFR treatment is an example of successful, although imperfect, biomarker development in oncology, and also demonstrates how an understanding of cancer biology should inform drug development at an early stage of the process.
However, the majority of patients who are selected for anti-EGFR therapy develop secondary resistance to the drug within 5-11 months. One of the main challenges in colorectal cancer research is to uncover the molecular mechanisms involved in this acquired resistance. An essential question is whether the resistance mechanisms derive from new mutation events or from existing clones -rare (and undetected) mutationcarrying cells that are present in the tumour at the start of treatment.
Results obtained by Misale et al. and Diaz et al. using in vitro experiments and mathematical models suggest that secondary resistance to anti-EGFR therapy is a fait accompli, because of the presence of KRASmutant clones in tumours that initially seem to express only wild-type KRAS. Both papers also present data from colorectal cancer patients whose tumours were classified, by biopsy, as KRAS wild-type at the initiation of therapy, but in whom the authors detected KRAS-mutant clones following treatment with either of two anti-EGFR drugs, cetuximab or panitumumab. These clinical studies were made possible by the use of 'liquid biopsies' in which circulating tumour DNA (ctDNA) was extracted from the serum of the patients' blood. The ctDNA was then studied using an ultrasensitive mutation-detection method called the BEAMing assay 3 . In both studies, the mutant clones were identified before drug resistance could be detected using standard tumour-imaging techniques.
These findings suggest that the same biological mechanism (in this case, KRAS mutation) can drive both primary and secondary drug
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Rare tumour cells with mutations that confer drug resistance can go undetected by standard testing procedures, according to two studies, which show that such mutations can be detected in patients' blood. See Letters p.532 and p.537
In a complementary study, Charrier and colleagues 4 investigated the role of the SRGAP2 genes in the development of spines -not those that permit us to walk upright, but dendritic spines. These are small protrusions from the surface of neurons that have an important role in the transmission of nerve impulses. Previous studies had documented the fact that humans have greater numbers and densities of dendritic spines than other primates and rodents 7, 8 , but the molecular mechanisms driving this feature were unknown. By studying cells from genetically modified mice and human brain tissue, the authors show that SRGAP2A promotes the maturation of spines and slows down the migration of neurons within the developing cerebral cortex, whereas the humanspecific SRGAP2C has opposite effects and so favours the formation of further spines (Fig. 1b) . These results suggest that the emergence of SRGAP2C could have contributed to expansion of the cortex and increase in spine numbers in human ancestors, and therefore to the evolution of brain function and plasticity (the ability to alter neural connections in response to new experiences).
Interestingly, Dennis et al. studied a group of young patients who had developmental disorders, and identified a few individuals -out of several thousand -who had DNA duplications or deletions that affected SRGAP2A or SRGAP2C. Although such numbers are too small to be statistically significant, they indicate that mutations in SRGAP2A and SRGAP2C could be linked to disease. This hypothesis is consistent with previous suggestions that the evolution of a bigger and more complex brain in the human lineage was accompanied by an increased susceptibility to neurological disorders 9 . Taken together, the findings reported by Dennis et al. and Charrier et al. significantly add to the current working version of the human genome, and provide an example of how human-specific gene duplications can modulate brain function. They also give functional context to the long-known prolonged immaturity of the developing human brain (a process known as neoteny) 10, 11 . By slowing spine maturation and promoting neuronal migration, SRGAP2C might allow the environment to have a more protracted influence on brain development than is possible during the shorter brain maturation times seen in other mammals, providing additional malleability.
Furthermore, Charrier et al. demonstrate how evolutionary hypotheses derived from the comparative genomics of humans and other primates can be tested in cell culture and animal models. This elegant work provides a launching point for unravelling a more detailed mechanistic understanding of the role of human-specific duplicated genes in brain development, and of their potential contribution to brain evolution and neurodevelopmental disorders. ■
